ES cell biopsy from blastocyst.
Filed under: Advanced Cell Technology, Athersys, Clinical Trials, Cytori, Embyonic Stem Cells, FDA, Geron, JNJ, Novocell, Osiris, Regenerative Medicine, adult stem cell, spinal cord injury, stem cells | Tagged: Clinical Trials, embryonic vs adult stem cell, embyryonic stem cell 2008, evolving clinical landscape, safety issues | No Comments »
Geron yesterday announced the issuance of US patent #7,326,572, helping to extend their patent protection around their embryonic stem (ES) cell platform technology in the area of treating type 1 diabetes. Currently, Geron owns an exclusive license from the Wisconsin Alumni Research Foundation (WARF) for James Tomson’s original ES patents. This license allows [...]
Filed under: Embyonic Stem Cells, Geron, Intellectual Property, Novocell, Regenerative Medicine, Type 1 diabetes | Tagged: culture conditions, embryonic germ cells, endoderm, patent protection | No Comments »
The FDA has scheduled an April 10, 2008 meeting to “discuss scientific considerations for safety testing for cellular therapy products derived from human embryonic stem cells.” This meeting will be followed by another meeting on April 11 that will “discuss updates on 1) research management related to the September 29, 2005 review of research programs [...]
Filed under: Advanced Cell Technology, Clinical Trials, Embyonic Stem Cells, FDA, Geron, Novocell, Regenerative Medicine, cell delivery, regulatory, stem cells | 1 Comment »
